Literature DB >> 12390156

Ocular perfusion abnormalities in diabetes.

Thomas A Ciulla1, Alon Harris, Paul Latkany, Heidi C Piper, Oliver Arend, Hana Garzozi, Bruce Martin.   

Abstract

PURPOSE: To review the role of ocular perfusion in the pathophysiology of diabetic retinopathy, one of the leading causes of irreversible blindness in the industrialized world.
METHODS: We carried out a Medline search of the literature published in English or with English abstracts from 1966 to 2000 using various combinations of relevant key words.
RESULTS: Hyperglycaemia leads to a wide variety of vascular abnormalities at the microvascular and macrovascular levels, including abnormal autoregulation.
CONCLUSION: Three major aspects of ocular perfusion in diabetic retinopathy require additional investigation. Firstly, the precise mechanisms that link elevated glucose to dysfunction of retinal vascular cells need to be identified. Secondly, those factors that lead to both capillary dropout and to angiogenesis, twin processes that are linked to tissue hypoxia and lead to excess perfusion, increased risk of extravascular leakage and frank haemorrhage, must be carefully delineated. Finally, once specific knowledge of disease fundamentals has been amassed, tests of therapies to reverse or prevent these pathological processes can move forward.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12390156     DOI: 10.1034/j.1600-0420.2002.800503.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand        ISSN: 1395-3907


  46 in total

1.  Effect of atorvastatin on ocular blood flow velocities in patients with diabetic retinopathy.

Authors:  A Ozkiris; K Erkiliç; A Koç; S Mistik
Journal:  Br J Ophthalmol       Date:  2006-09-14       Impact factor: 4.638

2.  Tracing method in the assessment of retinal capillary blood flow velocity by fluorescein angiography with scanning laser ophthalmoscope.

Authors:  Hideharu Funatsu; Kumi Sakata; Seiyo Harino; Yukio Okuzawa; Hidetaka Noma; Sadao Hori
Journal:  Jpn J Ophthalmol       Date:  2006 Jan-Feb       Impact factor: 2.447

3.  Insights from Genetic Model Systems of Retinal Degeneration: Role of Epsins in Retinal Angiogenesis and VEGFR2 Signaling.

Authors:  Yunzhou Dong; Xue Cai; Yong Wu; Yanjun Liu; Lin Deng; Hong Chen
Journal:  J Nat Sci       Date:  2017-01

4.  Investigational plasma kallikrein inhibitors for the treatment of diabetic macular edema: an expert assessment.

Authors:  Ashay D Bhatwadekar; Viral S Kansara; Thomas A Ciulla
Journal:  Expert Opin Investig Drugs       Date:  2020-01-31       Impact factor: 6.206

5.  En face Doppler total retinal blood flow measurement with 70 kHz spectral optical coherence tomography.

Authors:  Ou Tan; Gangjun Liu; Liu Liang; Simon S Gao; Alex D Pechauer; Yali Jia; David Huang
Journal:  J Biomed Opt       Date:  2015-06       Impact factor: 3.170

6.  Pilot study of optical coherence tomography measurement of retinal blood flow in retinal and optic nerve diseases.

Authors:  Yimin Wang; Amani A Fawzi; Rohit Varma; Alfredo A Sadun; Xinbo Zhang; Ou Tan; Joseph A Izatt; David Huang
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-02-11       Impact factor: 4.799

7.  The electrotonic architecture of the retinal microvasculature: diabetes-induced alteration.

Authors:  Atsuko Nakaizumi; Ting Zhang; Donald G Puro
Journal:  Neurochem Int       Date:  2012-02-13       Impact factor: 3.921

8.  Association between OCT-based microangiography perfusion indices and diabetic retinopathy severity.

Authors:  Alexander D Lin; Aaron Y Lee; Qinqin Zhang; Kasra A Rezaei; James Kinyoun; Ruikang K Wang; Cecilia S Lee
Journal:  Br J Ophthalmol       Date:  2016-11-15       Impact factor: 4.638

9.  Pharmacologic therapies for diabetic retinopathy and diabetic macular edema.

Authors:  Ehud Rechtman; Alon Harris; Hanna J Garzozi; Thomas A Ciulla
Journal:  Clin Ophthalmol       Date:  2007-12

10.  Adhesion molecules (ICAM-1 and VCAM-1) and diabetic retinopathy in type 2 diabetes.

Authors:  Taoufik Khalfaoui; Gérard Lizard; Amel Ouertani-Meddeb
Journal:  J Mol Histol       Date:  2007-12-30       Impact factor: 2.611

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.